IRAK4 and Alzheimer disease: Although the preliminary clinical activity of KT-474 in HS and AD in this study needs to be confirmed in future trials, it is notable that there was a consistent impact on objective, as well as subjective, clinical measures in both diseases with response kinetics that matched the PD effect on IRAK4 levels.